
NASDAQHealthcareBiotechnology
Latest quote
$5.68
−$0.12 · -2.07%
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
Previous close
$5.68
−$0.12 · -2.07%
Regular session · ET · Market data may be delayed.
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
Day range
Current $5.68
52-week range
Current $5.68
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
35
Expensive
Sentiment
68
Bullish
Risk
61
High Risk
Momentum
80
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
Day range
Current $5.68
52-week range
Current $5.68
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 5.09K USD | 19.99K USD | 5.28K USD | 3.73M USD | 166.94K USD |
| Gross profit | −5.09K USD | −19.99K USD | −5.28K USD | −3.73M USD | −166.94K USD |
| Research and development | 18.43M USD | 13.66M USD | 6.65M USD | 3.73M USD | 2M USD |
| Selling, general, and administrative | 7.44M USD | 5.16M USD | 4.57M USD | 4.69M USD | 2.62M USD |
| Operating expenses | 26.46M USD | 19.38M USD | 11.66M USD | 4.69M USD | 4.63M USD |
| Interest income | 1.36M USD | 955.27K USD | 1M USD | 63K USD | 6.26K USD |
| Interest expense | — | — | 133.42K USD | — | 772.8K USD |
| Depreciation and amortization | 4K USD | 13.94K USD | 5.28K USD | 319.71K USD | 162K USD |
| Operating income | −26.46M USD | −19.38M USD | −11.66M USD | −8.43M USD | −6.65M USD |
| Net income | −24.87M USD | −19.58M USD | −11.98M USD | −11.32M USD | −15.51M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.